Clinical trials shows MAST as a Phase 1, so my guess is Yuman has either misspoken, or is simply referring to it as a Phase 2 because its moved to an expansion cohort for a specific indication (cholangio), where MAST started in Phase 1 as a 'basket' study for multiple cancer types. I wouldn't read too much into that.
Clinical trials shows MAST as a Phase 1, so my guess is Yuman...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
0.001(1.04%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 4.9¢ | 4.8¢ | $123.1K | 2.533M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 69 | 7865458 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 2767851 | 22 |
View Market Depth
| Last trade - 11.58am 04/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |